RE: Potential Investors4 Jan 2024 16:29
The Gaurdian....Company to Watch 2024!!!
4th January 2024
Genflow Biosciences
Longevity is not just for billionaires, says Dr Eric Leire, the founder and chief executive of Genflow Biosciences, which in December 2022 became the first anti-ageing biotech to list in Europe.
The London-listed and headquartered company, which has its labs in Belgium and an office in Cambridge, Massachusetts, is developing gene therapies for longer, healthier lives.
The company’s work is based on a rare mutation of the SIRT6 gene found in people who live beyond the age of 100, which was discovered by Dr Vera Gorbunova’s team at the University of Rochester in 2019. She chairs Genflow’s scientific advisory board.
“Some people are lucky to have the good gene, and what we want to do is share that luck with everybody,” says Leire, who previously worked for Pfizer and Schering-Plough.
Genflow plans to test an experimental therapy on people with an age-related liver disease called NASH in early 2025. It is also developing a therapy for Werner syndrome, a rare accelerated ageing disease, by which SIRT6 messenger RNA delivers the gene to the skin. Genflow is also launching a programme to prevent age-related loss of muscle mass, funded by new research grants.
It started trading on the OTCQB venture market in the US in the summer, to expand its reach to US investors. As an early-stage biotech, Genflow is a risky investment; its London-listed shares have lost nearly 90% of their value in the first year of trading. But it is certainly one to watch. The longevity science sector is forecast to reach $2bn (£1.6bn) by 2030, according to Insight Analytics. Julia Kollewe
Sign In
Follow the stocks
